Topic
Pipelines & Trials
Drug pipelines, readouts at medical meetings (ASCO, ESMO, AHA, ADA, AAIC, ASH), FDA decision dates, and what the trial data really show.
- Body & Longevity
AUF1 Gene Therapy Limited Muscle Loss After Injury in Mice
Mice kept near normal strength after a severe muscle injury when given extra AUF1, by virus or by mRNA. Two authors cofounded the company developing it, and no human has received it.
- Body & Longevity
An Oral Pill for Angioedema Attacks: Relief in 1.3 Hours
A crossover trial in a rare disease, funded by the drugmaker: each patient treated one attack with the pill and one with placebo. The result is large and the analysis smaller than the enrollment.
- Body & Longevity
A Parkinson's Pill That Skips Dopamine Cut Off Time by 37 Minutes
A new mechanism, a positive primary endpoint and a modest effect size. Everything here comes from a company release and a congress talk, not a peer reviewed paper.
- Body & Longevity
Seven FDA Decisions Due by Christmas, and the Trials Behind Them
Every date below comes from the company itself. CagriSema has no published goal date, only a quarter. One file arrives after an advisory committee voted 9 to 3 against.
- Body & Longevity
Semaglutide's Heart Benefit Is Not Just About Weight Loss
Known risk factors explain at most about half of the 20% drop in heart events, and the frailest patients still benefit. Widening eligibility to a BMI of 25 is a different question.
- Body & Longevity
Orforglipron Worked Across Menopause Stages, With One Asterisk
Women lost 12.8% to 14.4% of their weight on the top dose without diabetes. The diabetes trial tells a shakier story, built partly on a subgroup of 10 women.
- Body & Longevity
One Insulin Shot a Week: What the Efsitora Approval Covers
Efsitora matched daily insulin on HbA1c in four trials and trades 365 injections for 52. In type 1 diabetes, severe lows were three times as common, which is why the label stops at type 2.
- Body & Longevity
Lp(a): The Heart Risk Factor Science Still Can't Treat
Pelacarsen lowered Lp(a) in 8,323 HORIZON patients, but heart attacks and strokes did not fall. Why that gap between biomarker and outcome matters.
- Body & Longevity
The First PCSK9 Pill Is Here. The Proof Still Comes From a Shot
A daily tablet now cuts LDL by more than half, while the injectable version of the same drug class was linked to 20% fewer deaths in people with no prior heart attack.
- Body & Longevity
Retatrutide Takes Weight Off. Viking Bets a Monthly Shot Keeps It
Retatrutide's 20.8% assumes nobody quit, and Viking's 90% comes from a group of 11. The numbers behind the two biggest obesity drug headlines of September.
- Body & Longevity
Aprocitentan: Another Dial for Hard to Control Blood Pressure
Against placebo, the endothelin blocker lowered systolic pressure by about 4 mmHg on top of three drugs. New post hoc data on obesity and kidney risk.
- Body & Longevity
CagriSema and EloraTZP Both Beat Tirzepatide. Read the Doses
Novo won at the low end of the dose range, 12.4 versus 9.1 percent. Lilly won at the top, 23.3 versus 14.8, and lost up to one patient in four to side effects.
- Body & Longevity
Myostatin Blockers Cut GLP-1 Muscle Loss. Strength Is Unproven
Trevogrumab and apitegromab saved kilograms of lean tissue in phase 2 trials, but no study has yet shown that it makes anyone stronger.
- Body & Longevity
A GLP-1 Pill Against Insulin: What ACHIEVE-4 Proved for the Heart
Orforglipron cleared a heart safety bar against insulin glargine, 4.2 versus 5.0 percent, and posted a mortality gap the trial was never built to prove.
- Body & Longevity
The Pill Duel: Orforglipron Beats Oral Semaglutide Head to Head
ACHIEVE-3, 1,698 adults, 52 weeks: in the primary analysis HbA1c fell 1.91 points against 1.47. A real head to head, run by one of the duelists.
- Body & Longevity
The Race to Keep Muscle on GLP-1s Reaches Phase 2
Sironax's FORGE-LM trial is half enrolled. The endpoint is body composition, which is the right question. Enrollment, though, is not a result.
Get Facts First, every Sunday
One email a week: the 5 facts that mattered in AI, health and longevity, each checked against the original source. No spam. Unsubscribe in one click.
By subscribing you agree to receive the newsletter. See the privacy policy.